We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Neurocrine Biosciences Inc | LSE:0K6R | London | Ordinary Share | NEUROCRINE BIOSCIENCES ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 91.67 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.89B | 249.7M | 2.5414 | 54.68 | 13.65B |
From Apr 2022 to Apr 2024
TIDMDNL TIDMTTM
RNS Number : 3056Y
Diurnal Group PLC
05 September 2022
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
Hot Features
Premium
1. KEY INFORMATION
(a) Full name of discloser: Diurnal Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Diurnal Group PLC
Use a separate form for each offeror/offeree
------------------
(d) Is the discloser the offeror or the offeree? OFFEREE
------------------
(e) Date position held: 2 September 2022
The latest practicable date prior to the disclosure
------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect N/A
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates
Class of relevant security: Ordinary shares of GBP0.05 each
Interests Short positions
------------------- ------------------
Number % Number %
----------- ------ ----------- -----
(1) Relevant securities owned and/or controlled: Nil Nil Nil Nil
----------- ------ ----------- -----
(2) Cash-settled derivatives: Nil Nil Nil Nil
----------- ------ ----------- -----
(3) Stock-settled derivatives (including options) and agreements to Nil Nil Nil Nil
purchase/sell:
----------- ------ ----------- -----
Nil Nil Nil Nil
TOTAL:
----------- ------ ----------- -----
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: N/A
Details, including nature of the rights concerned and relevant percentages: N/A
----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
a) Ordinary Shares held by directors of Diurnal Group PLC
% of Issued
Number of Ordinary Share Capital
Shares (170,040,825)
Richard Ross 2,284,047 1.34%
------------------- ---------------
Richard Bungay 337,578 0.19%
------------------- ---------------
John Goddard 228,574 0.13%
------------------- ---------------
Samuel Williams 113,819 0.06%
------------------- ---------------
Alan Raymond 66,849 0.03%
------------------- ---------------
b) Options and awards held by directors of Diurnal Group PLC
Long Term Incentive Plan:
Maximum Date of Exercise Vesting Exercise
number of Grant Price date Period
share awards
Richard Ross 71,743 04/12/2018 Nil Vested Expiry
04/12/2028
-------------- ----------- --------- ------------ ------------
Richard Ross 82,431 10/01/2020 Nil Vesting Expiry
10/01/2023 10/01/2025
-------------- ----------- --------- ------------ ------------
Richard Ross 137,860 18/12/2020 Nil Vesting Expiry
18/12/2023 18/12/2025
-------------- ----------- --------- ------------ ------------
Richard Ross 155,899 14/12/2021 Nil Vesting Expiry
31/12/2024 31/12/2026
-------------- ----------- --------- ------------ ------------
Richard Bungay 242,857 08/05/2017 GBP0.05 Vested Expiry
18/05/2027
-------------- ----------- --------- ------------ ------------
Richard Bungay 56,877 17/10/2017 GBP0.05 Vested Expiry
17/10/2027
-------------- ----------- --------- ------------ ------------
Richard Bungay 204,083 04/12/2018 Nil Vested Expiry
04/12/2028
-------------- ----------- --------- ------------ ------------
Richard Bungay 239,172 10/01/2020 Nil Vesting Expiry
10/01/2023 10/01/2025
-------------- ----------- --------- ------------ ------------
Richard Bungay 411,764 18/12/2020 Nil Vesting Expiry
18/12/2023 18/12/2025
-------------- ----------- --------- ------------ ------------
Richard Bungay 374,434 14/12/2021 Nil Vesting Expiry
31/12/2024 31/12/2026
-------------- ----------- --------- ------------ ------------
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:
(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
---
Date of disclosure: 2 September 2022
Contact name: Mike Scott
--------------------
Telephone number: +44 (0)20 3727 1000
--------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FEELELFBLKLXBBE
(END) Dow Jones Newswires
September 05, 2022 08:36 ET (12:36 GMT)
1 Year Neurocrine Biosciences Chart |
1 Month Neurocrine Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
